Kornimate/medical-research-clean huggingface dataset:
persistence of symptoms after improvement of acute covid-19

Conditions: Corona Virus Infection

Summary: coronavirus disease pandemic has been started in late 2019. survivors of covid-19 are significantly more likely to develop clinical sequelae three months after discharge from the hospital than those without covid-19 infection. this is true not only for general and respiratory symptoms but also for cardiovascular and psychosocial symptoms. this suggests that these symptoms may indeed be the sequelae of recovery for covid-19 survivors. so, we aimed to detect the prevalence and to evaluate the type of symptoms that could persist after the recovery from covid19 infection in sohag governorate, egypt.

about one hundred patients who were test positive for sars-cov2 and were improved and discharged from sohag isolation hospitals and isolation department for covid19 in sohag university hospitals during the period from 15th may, 2020 to 25th july, 2020 will be included in our study. patient improvement and discharge criteria include 10 day from symptoms onset in addition to 3 day free of fever and respiratory symptoms. patients with severe complex illness, pregnant or lactating females and patient who refuse to participate or give complete detailed history will be excluded from the study. the study protocol will be approved by the scientific research ethical committee, faculty of medicine, sohag university a control group of healthy volunteer who were age and sex matched to our patient were included after taken informed consent according to sohag university ethical committee, the baseline data will be collected from sohag isolation hospital of covid19, then the researchers will perform interviews with all participants through mobile phone. the interview will include: * name (optional) * age * sex * occupation * presence of dm, htn or any chronic illness * asking about smoking * the date of catching covid19 infection * asking about symptoms of covid19 infection and duration of each symptom. * asking about any residual symptoms as: fatigue, myalgia, arthralgia, chest pain, dyspnea, dry cough, productive cough, sore throat, anosmia, loss of taste sensation, nausea, anorexia, diarrhea, redness of the eye, headache, confusion and depression statistical analysis: data will be analyzed using stata version 14.2 (statistical software: release 14.2 college station, tx: stata corp lp). quantitative data will be represented as mean, standard deviation, median and range. normally distributed. qualitative data will be presented as numbers and percentages. chi square test will be used for comparison of percentages in different groups. p value will be considered significant if it was less than 0.05.

Eligibility criteria:
inclusion criteria: positive for sars-cov2 exclusion criteria: * patients with severe complex illness, pregnant or lactating females and patient who refuse to participate or give complete detailed history

Keywords: persistent symptoms recovery covid-19
study in infants with infantile hemangioma to compare propranolol gel to placebo

Conditions: Infantile Hemangioma

Summary: there is an unsatisfied medical need for a first-line treatment of localized uncomplicated proliferating infantile hemangioma with a good benefit/risk profile. pierre fabre dermatologie has developed a new formulation of propranolol (v0400 gl 01a) which is a topical gel adapted to paediatric use. the objective of this study is to evaluate topical propranolol efficacy and safety in the management of localized hemangioma.


Eligibility criteria:
main inclusion criteria: * only one proliferating infantile hemangioma present anywhere on the body except on the head, the neck, the hands and on the diaper area, with largest diameter diameter ≥ 1cm and ≤ 5 cm. main exclusion criteria: * more than one infantile hemangioma with largest diameter ≥ 1cm * medically unstable health status that may interfere with his/her ability to complete the study * infantile hemangioma requires, according to investigator's judgment, a systemic treatment * the patient has previously been administered treatment for ih or surgical and/or medical procedures (e.g. laser therapy) have been performed to treat the ih

Keywords: propranolol gel hemangioma capillary neoplasm vascular tissue neoplasm by histologic type neoplasm therapeutic uses pharmacologic actions adrenergic beta-antagonists adrenergic antagonist adrenergics agent neurotransmitter agent molecular mechanism of pharmacological action physiological effects of drugs
pocus for difficult peripheral access in the emergency department - a rct

Conditions: Vascular Access; Emergencies

Summary: peripheral intravenous line insertion is the most commonly performed invasive procedure in the emergency department (ed). the research hypothesis is that a biplane sonographic approach (i.e., an out-of-plane and in-plane view) might be superior to a mono-plane approach (i.e., an out-of-plane or in-plane view) obtaining a peripheral vascular access among difficult patients admitted to the ed

peripheral intravenous line insertion is the most commonly performed invasive procedure in the emergency department (ed). in some studies, difficult vascular access population was about 33% of evaluated patients and for most of them the "blind" method (i.e., palpation) fails in the line insertion. ultrasound guidance often increase the success rate among these patients. two basic techniques were proposed for sonographic guidance, a transversal or a longitudinal approach to the chosen vessel (i.e., out-of-plane or in-plane view, respectively, "mono-plane" approach). the availability of hand-held sonographic devices is increasing the number of emergency department were this guidance is used in a difficult vascular access population. the butterly iq+ device is now able to show out-of-plane and in-plane views, simultaneously, the so called bi-plane view. aim of this randomized controlled trial is to test if a bi-plane sonographic vision might be able to increase the performance of trained operators in obtaining a peripheral vascular access among difficult patients admitted to the ed. the present study will be a randomized controlled, 2-arm, nonblinded trial held at the città della salute e della scienza di torino, university hospital, turin, italy. all healthcare workers already trained in ultrasound-guided vascular access will be considered eligible for the study (i.e., emergency physicians, residents, nurses) after an ad hoc brief (2 hours) training on the study. this will be a "real world" study, each provider will be free of choosing the device he/she thought appropriate for each patient (in terms of length, gauge, type - peripheral midline will be included in the italian center). using a computerized permuted blocks of random sizes, enrolled patients will be randomized in a 1:1 ratio to be evaluated using either the "standard" ultrasound-guided approach (out-of-place or in-plane view) or the bi-plane view (i.e. out-of-place and in-plane view, simultaneously).

Eligibility criteria:
inclusion criteria: at least one of the following criteria have to be present along with the need for a peripheral access * chronic renal disease/ongoing dialysis; * sickle cell anemia; * prolonged and/or frequent use of i.v. drugs; * difficult vascular access (after a first attempt or self-reported); * previously need for more than one attempts / ultrasound guidance for getting a peripheral vascular access. exclusion criteria: * no consent to participate in the study.

Keywords: point-of-care ultrasound emergency department
alcohol brief intervention plus personalized mobile chat-based intervention for high-risk drinking university students

Conditions: Alcohol Drinking in College

Summary: the aims of this pilot study are: 1. to examine the factors associated with alcohol drinking and alcohol use disorder 2. to examine the effect of face-to-face alcohol brief intervention on drinking reduction 3. to examine the effect of a continuous interactive chat-based intervention via "whatsapp" on drinking reduction 4. to explore the perception of face-to-face alcohol brief intervention 5. to explore the perception of continuous interactive chat-based intervention via instant messaging mobile application "whatsapp"

according to the department of health, majority of people in hong kong started to develop drinking habit at 18-21 years of age in 2014/2015. amongst them, 16.8% had scored higher than 3 in the alcohol use disorders identification test for consumption (audit-c) (an abbreviated version of the alcohol use disorders identification test, or audit, designed by the world health organization(who)), while 3.5% had even scored 8 or above in the test. with higher prevalence to begin drinking within 18 and 23 years old, university students could have established higher tendency of harmful drinking and alcohol dependence as compared with other age groups. therefore, early interventions such as the evidence-based alcohol brief intervention (abi) suggested by the who are particularly needed to target university drinkers who are 5% more likely to develop higher frequency of drinking in later of their lives compared with other age groups.

Eligibility criteria:
inclusion criteria: * hong kong resident aged 18 to 26 inclusive * scored 5-19 inclusive in the alcohol use disorder identification test (audit) * able to communicate in chinese and read chinese * using a phone with instant messaging mobile application "whatsapp" installed for communication exclusion criteria: * students with communication barrier (either physically or cognitively) * currently participating in other alcohol treatment services or clinics.

Keywords: chat-based intervention alcohol brief intervention high-risk drinking university students audit instant messaging whatsapp
fatigue in chronic haemodialysis patients: an experience sampling method study

Conditions: Fatigue; End Stage Renal Disease

Summary: to investigate the course and diurnal change of fatigue symptoms and haemodialysis related symptoms in chronic haemodialysis patients, its relation to haemodialysis treatment and the association with other factors by implementing an ecological momentary assessment procedure incorporated in a webapplication.

the course and diurnal change of fatigue symptoms in the daily life of chronic haemodialysis (hd) patients, its relation to haemodialysis treatment and the association with other factors such as mood, activities, location and social context will be evaluated during 7 consecutive days by using an ecological momentary assessment (ema) procedure, incorporated into a webapplication. using an ema procedure will more accurately represent fatigue symptoms and its relation to other factors in the daily life of chronic hd patients compared to conventional measurement instruments (i.e. questionnaires evaluating fatigue over a period of a week or more, which are therefore liable to a recall bias).

Eligibility criteria:
inclusion criteria: * end stage renal disease requiring chronic haemodialysis treatment currently being treated for at least 6 months. * good understanding of dutch based on clinical judgment (since the web-application is only available in the dutch language). exclusion criteria: * the participant cannot independently handle the web-application based on clinical judgment. * dementia or insufficient cognitive skills to handle the web-application based on clinical judgement by the attending physician.

Keywords: fatigue haemodialysis ecological momentary assessment
incidence of delirium in critically ill patients in a dutch university hospital

Conditions: Delirium

Summary: the objective of this study is to determine the incidence of delirium in adults patients who are admitted at the critical care unit of a dutch university hospital. the primary aim is to determine the incidence of delirium and to determine risk factors for this group of patients to develop a prediction model. a secondary aim is to find differences between delirious patients and non-delirious patients on different aspects of diagnostics, treatment and care, outcome, length of stay, and inflammation. according to dutch law, the need to obtain informed consent was waived by the committee on research involving human subjects (cmo) of nijmegen for this observational study (2007/283).


Eligibility criteria:
inclusion criteria: * all adult patients (18 years and older) admitted at the critical care unit of our hospital exclusion criteria: * not able to understand dutch * patients with serious hearing and visibility disabilities * mentally retarded patients

Keywords: delirium critical care risk factors prediction
evaluation of thoracic tumors with 18f-fmt and 18f-fdg pet-ct a clinicopathological study

Conditions: Non-Small Cell Lung Cancer

Summary: l-\[3-18f\]-α-methyltyrosine (18f-fmt) is an amino-acid tracer for positron emission tomography (pet). the aim of this study was to determine whether pet-ct with 18f-fmt provides additional information for the preoperative diagnostic workup as compared with 18f-fdg pet. tumor uptake of 18f-fmt was compared with several immunohistochemical markers including l-type amino acid transporter 1 (lat1).


Eligibility criteria:
inclusion criteria: * patients with indeterminate pulmonary nodule suspicious of lung cancer exclusion criteria: * patients with other malignancies and those who had received cancer treatment within the past 5 years were excluded.

Keywords: fluorine-18-α-methyltyrosine, positron emission tomography, fluorine-18-fluorodeoxyglucose, lung cancer,
natural history of mtbi-related convergence insufficiency & effectiveness of vision therapy for mtbi-related ci

Conditions: Convergence Insufficiency

Summary: the design of this project is a pilot study, a type of feasibility study conducted in preparation for subsequent rcts that will assess the effectiveness of office-based vergence/accommodative therapy with movement (obvam) for mtbi-related convergence insufficiency.

the design of this project is a pilot study, a type of feasibility study conducted in preparation for subsequent rcts that will assess the effectiveness of interventions or therapies. in this application, we refer to this pilot and feasibility study as a pilot clinical trial (pct). this feasibility pct aims to identify potential challenges, logistical issues, and unforeseen complications. to do this, we will examine various feasibility aspects, including recruitment and retention, randomization, intervention protocols, outcome measures, ethical considerations, safety monitoring, resource availability, and stakeholder feedback. by conducting this pct, we can test our procedures and gather preliminary data. the primary objectives of this feasibility pct are to 1) determine the feasibility of conducting future full-scale rcts by evaluating the effectiveness of a novel vergence/accommodative/move (obvam) therapy program for young adults with mtbi-ci and 2) better understand the progression and stability (i.e., natural history) of mtbi-ci over the 6 weeks following enrollment.

Eligibility criteria:
inclusion criteria: * • age 18 to 35 years inclusive * medical diagnosis of mtbi or concussion \> 1 month ago and no longer than 6 months ago * convergence insufficiency symptom (ciss score) ≥ 21 * best-corrected va of 20/25 or better in both eyes at distance \& near * willingness to wear refractive correction, if indicated * random dot stereopsis of 500 arcsec or better (randot stereo test) * receded npc of ≥6 cm * insufficient pfv (\< 15∆ or pfv blur point less than twice the near exophoria magnitude) * wearing refractive correction for cycloplegic refractive errors of: * ≥ +1.25 d se hyperopia or ≥ -1.00 d se myopia in either eye * ≥ 1.25 d astigmatism in either eye, ≥ 1.00 d se anisometropia * astigmatism axis within ±10 degrees if magnitude is ≤1.00 d and within ±5 degrees if \>1.00 d exclusion criteria: * • no previous treatment for ci * no previous diagnosis of ci from an ophthalmologist or optometrist * no medications known to affect accommodation or vergence * investigator \& patient willing to forgo all other ci treatment other than that assigned by randomization

Keywords: convergence insufficiency vision therapy mtbi concussion office-based vergence/accommodative therapy
rapamycin in with high-dose etoposide and cytarabine in relapsed/refractory aggressive lymphoid malignancies

Conditions: ALL; Burkitt's Lymphoma; Lymphoblastic Leukemia; CML

Summary: assess the safety, tolerability and efficacy of rapamycin in combination with hivac in relapsed and refractory patients with aggressive lymphoid malignancies.


Eligibility criteria:
inclusion criteria: * advanced lymphoid leukemia (primary refractory all; relapsed all; cml in lymphoid accelerated phase or blast crisis; relapsed or refractory burkitt's lymphoma; relapsed or refractory t-cell adult leukemia/lymphoma; relapsed or refractory lymphoblastic lymphoma * \>= 18 and \ = 4 weeks able to consume oral medication required initial laboratory values: creatinine \<= 2.0mg/dl, total or direct bilirubin \<= 1.5 mg/dl, sgpt(alt) \<=uln, glucose \< 200 mg/dl, negative pregnancy test for women with child bearing potential exclusion criteria: * subjects must not be receiving any chemotherapy agents (except hydroxyurea) * subjects must not have received high-dose ara-c within 6 months of relapse * subjects must not be receiving growth factors, except for erythropoietin * no currently active second malignancy other than non-melanoma skin cancers * no subjects with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, mi within the last 6 months or serious uncontrolled cardiac arrhythmia * subjects taking carbamazepine, rifabutin, rifampin, rifapentine, st. john's wort, clarithromycin, cyclosporine, diltiazem, erythromycin, telithromycin, verapamil, tacrolimus * known hiv positivity or aids-related illness * evidence of cerebellar dysfunction or prior history of cerebellar dysfunction with ara-c administration * pregnant or lactating * uncontrolled infection * taking fluconazole, voriconazole, itraconazole and ketoconazole currently or within one week of study entry

Keywords: all burkitt's lymphoma adult t-cell leukemia/lymphoma lymphoblastic leukemia cml in lymphoid blast crisis patients hivac rapamycin
lithium drug-drug interaction study with lurasidone hcl

Conditions: Schizophrenia

Summary: the purpose of this study is to evaluate the drug-drug interaction effect between lithium and lurasidone hcl.

to compare the steady state pharmacokinetic profile of lurasidone 120 mg qd when administered alone vs. the steady state pharmacokinetic profile of lurasidone 120 mg qd when coadministered with steady state lithium 600 mg bid.

Eligibility criteria:
inclusion criteria: 1. diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform. 2. females who participate in this study: * are unable to have children-or- * are willing to remain abstinent from day -5 until 90 days after discharge; 3. males must be willing to remain sexually abstinent or use an effective method of birth control (e.g. condom) from day -5 until 90 days after discharge. 4. able and agree to remain off of prior antipsychotic medication for the duration of the study. exclusion criteria: 1. presence or history (within the last year) of a medical or surgical condition (e.g. gastrointestinal disease) that might interfere with the absorption, metabolism, or excretion of orally administered lurasidone. 2. positive test results within 30 days prior to the start of the study for: 3. participated in another clinical trial or receiving an investigational product within 30 days prior to drug administration. 4. use of concomitant medications that prolong the qt/qtc interval within 14 days prior to day - 5 to follow-up 5. use of a monoamine oxidase inhibitor within 21 days prior to day 1 to restabilization. 6. received depot neuroleptics unless the last injection was at least 1 treatment cycle before day -5.

Keywords: lithium ddi with lurasidone hcl male/female, schizophrenia patients
robotic and manual cochlear implantation: an intra-individual study of speech recognition and electrode holder position (icrobman)

Conditions: Cochlear Hearing Loss

Summary: cochlear implantation (ci) allows rehabilitation for patients with severe to profound hearing impairment. although the use of a robotic assistant provides technical assistance to the surgeon, the assessment of the impact of its use on auditory outcomes remains uncertain, due to inter-individual variability of preoperative audiometric thresholds and the various possible intrascalar positions of the electrode array. wthe investigators aim to compare the hearing results of patients who underwent bilateral cochlear implantation, one side was performed with manual insertion and the other side with robot-assisted insertion. the electrode array intrascalar positioning and the surgery duration were also studied. this retrospective intra-individual study involved 10 patients who underwent bilateral cochlear implantation. the unique composition of this cohort enabled the investigators to utilize each patient as their own control.

cochlear implantation (ci) allows rehabilitation for patients with severe to profound hearing impairment. although the use of a robotic assistant provides technical assistance to the surgeon, the assessment of the impact of its use on auditory outcomes remains uncertain, due to inter-individual variability of preoperative audiometric thresholds and the various possible intrascalar positions of the electrode array. the investigators aim to compare the hearing results of patients who underwent bilateral cochlear implantation, one side was performed with manual insertion and the other side with robot-assisted insertion. the electrode array intrascalar positioning and the surgery duration were also studied. this retrospective intra-individual study involved 10 patients who underwent bilateral cochlear implantation. the unique composition of this cohort enabled the investigators to utilize each patient as their own control.

Eligibility criteria:
inclusion criteria: * bilateral cochlear implantation at a tertiary referral center * one side manual * one side robot-assisted exclusion criteria: * opposition * under curatorship